<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Kilic, E.</title>
    <link>http://repub.eur.nl/res/aut/7033/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Genetics of uveal melanoma and cutaneous melanoma: two of a kind? (Article)</title>
      <link>http://repub.eur.nl/res/pub/25596/</link>
      <pubDate>2010-01-01T00:00:00Z</pubDate>
      <description>Cutaneous melanoma and uveal melanoma both derive from melanocytes but show remarkable differences in tumorigenesis, mode of metastatic spread, genetic alterations, and therapeutic response. In this review we discuss the differences and similarities along with the genetic research techniques available and the contribution to our current understanding of melanoma. The several chromosomal aberrations already identified prove to be very strong predictors of decreased survival in CM and UM patients. Especially in UM, where the overall risk of metastasis is high (45%), genetic research might aid clinicians in selecting high-risk patients for future systemic adjuvant therapies.</description>
    </item> <item>
      <title>Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma (Article)</title>
      <link>http://repub.eur.nl/res/pub/17541/</link>
      <pubDate>2009-09-01T00:00:00Z</pubDate>
      <description>Background: Recently, oncogenic G protein alpha subunit q (GNAQ) mutations have been described in about 50% of uveal melanomas and in the blue nevi of the skin.Methods:GNAQ exon 5 was amplified from 75 ciliary body and choroidal melanoma DNAs and sequenced directly. GNAQ mutation status was correlated with disease-free survival (DFS), as well as other clinical and histopathological factors, and with chromosomal variations detected by FISH and CGH.Results:Of the 75 tumour DNA samples analysed, 40 (53.3%) harboured oncogenic mutations in GNAQ codon 209. Univariate and multivariate analysis showed that GNAQ mutation status was not significantly correlated with DFS.Conclusion:The GNAQ mutation status is not suitable to predict DFS. However, the high frequency of GNAQ mutations may render it a promising target for therapeutic intervention.</description>
    </item> <item>
      <title>Adipocyte differentiation defect in mesenchymal stromal cells of patients with malignant infantile osteopetrosis (Article)</title>
      <link>http://repub.eur.nl/res/pub/24617/</link>
      <pubDate>2009-08-07T00:00:00Z</pubDate>
      <description>Background: Malignant infantile osteopetrosis (MIOP) is a disorder of osteoclasts characterized by defective bone resorption and death in infancy. The multipotent mesenchymal stromal cells (MSC) and their progeny (osteoblasts) are major components of the bone marrow (BM) microenvironment and are found in close contact with cells of hematopoietic origin, including osteoclasts. We hypothesized that MSC defects may be associated with osteoclast dysfunction and osteopetrosis phenotype. Methods: BM MSC, obtained from six patients with MIOP, were expanded in vitro and characterized by morphology, plastic-adherence, immunophenotype and multilineage differentiation potential. Results: Physical and immunophenotypic characteristics of patient MSC were similar to healthy age-matched controls. However, an isolated in vitro differentiation defect toward adipogenic lineage was demonstrated in patient MSC and confirmed by low or absent expression of adipogenic transcripts (peroxisome proliferator-activated receptor-γ, adipophilin, stearoyl-CoA desaturase, leptin and adiponectin) upon induction of adipogenesis. Following BM transplantation, minimal improvement in adipogenic potency of MSC was demonstrated by Oil Red O staining. Discussion: MIOP is associated in vitro with a failure of MSC to differentiate into an adipogenic lineage, suggesting a BM microenvironment defect. The defect may contribute to osteoclast dysfunction, or may be attributed to the effect of the osteopetrotic marrow environment. Further investigations should determine the pathophysiologic importance of this novel defect, and could perhaps contribute to consideration of MSC therapy in MIOP.</description>
    </item> <item>
      <title>Chromosome 3 intratumor heterogeneity in uveal melanoma (Article)</title>
      <link>http://repub.eur.nl/res/pub/27237/</link>
      <pubDate>2009-02-01T00:00:00Z</pubDate>
      <description>PURPOSE. To investigate the presence of focal or diffuse heterogeneity of monosomy 3 in uveal melanoma, by using fluorescence in situ hybridization (FISH). METHODS. Direct interphase FISH in a series of 151 uveal melanomas revealed 82 tumors with loss of chromosome 3. Tumors with monosomy 3 were suspected to be heterogeneous if there were low percentages of monosomy 3, triploid clones, inconsistencies between FISH on centromere 3 and the long arm of chromosome 3, or discrepancies between fine-needle-aspiration biopsies (FNABs) and the main tumor. These tumors (n = 16), all choroidal melanomas, were selected and analyzed for intratumor heterogeneity by using FISH on paraffin-embedded tissue sections. RESULTS. Different sections of each tumor were evaluated with FISH: 6 tumors showed monosomy 3 in the same percentage throughout the tumor, and 10 showed multiple clones with different percentages of monosomy 3. However, these tumors did not show focal heterogeneity with respect to chromosome 3 status, and differences in monosomy 3 distribution between the base and apex of the tumor could not be identified. CONCLUSIONS. Although a small number of uveal melanomas show heterogeneity for chromosome 3, it does not affect survival. In the presence of triploid clones, the loss of chromosome 3 is more difficult to interpret. In general, tumor biopsies in uveal melanoma provide an accurate prediction of the patient's prognosis. Copyright </description>
    </item> <item>
      <title>Gene expression profiling in uveal melanoma: Two regions on 3p related to prognosis (Article)</title>
      <link>http://repub.eur.nl/res/pub/29410/</link>
      <pubDate>2008-10-01T00:00:00Z</pubDate>
      <description>PURPOSE. Although studies on uveal melanoma (UM) revealed prognostic significance of chromosomal aberrations, they resulted in classification errors in survival prediction. A robust prognostic classifier with strong predictive value and further insight in genes responsible for poor prognosis were obtained by performing a gene-expression profile in tumors of UM patients for which extensive clinical, histopathologic, cytogenetic, and follow-up data were available. Furthermore, the UM microarray expression data were compared with cytogenetic data. METHODS. Gene-expression profiles of 46 UMs were obtained with microchip assays. Data were analyzed with cluster-analysis and predictive analysis of microarrays (PAM) software and validated with real-time PCR. The prognostic significance of UMs with specific molecular signatures was determined. Furthermore, LAP analysis resulted in the identification of differentially expressed chromosomal regions. RESULTS. The primary UMs were classified in two distinct molecular classes with a strong prognostic value (P &lt; 0.001; hazard ratio 7.7). Classifier gene sets for microarray class and disease-free survival were validated with real-time PCR, and the predictive value of the UM class marker set was validated with gene-expression profiles of tumors provided by other institutions, showing a sensitivity of 0.93 and specificity of 1.00 for class II tumors. A locally adaptive statistical procedure identi-fied two regions on the short arm of chromosome 3 with decreased gene-expression in tumors with shorter disease-free survival. CONCLUSIONS. Microarray classification outperforms known prognostic indicators for UM, such as clinical, histopathologic, and cytogenetic parameters. In addition, the identified regions with lower expressed genes on 3p could harbor genes that are responsible for the poor prognosis of patients with UM. Copyright </description>
    </item> <item>
      <title>Expression of the SST receptor 2 in uveal melanoma is not a prognostic marker (Article)</title>
      <link>http://repub.eur.nl/res/pub/29773/</link>
      <pubDate>2008-08-07T00:00:00Z</pubDate>
      <description>Introduction: Uveal melanoma (UM) cells and neurohormone-producing cells both originate from the neural crest. Somatostatin receptors subtype 2 (SSTR2) are over-expressed in several tumors, often from neuroendocrine origin, and synthetic antagonists like octreotide and octreotate are being used as diagnostic or therapeutic agents. We investigated the SSTR2 expression in UM, and determined whether this expression was related to prognosis of the disease. Materials and methods: UM cell lines and fresh primary UM samples were tested for SSTR2 expression by autoradiography (AR) using 125I-Tyr3-octreotate. Furthermore, UM cell lines were analyzed for SSTR2 mRNA expression with quantitative real-time RT-PCR. Results: Using AR, cell-surface SSTR2 expression was demonstrated in two UM metastatic cell lines, but no expression was detected in three cell lines derived from primary UM. However, all primary and metastatic UM cell lines showed mRNA expression levels for SSTR2 using quantitative real-time RT-PCR. Only three of 14 primary UM demonstrated moderate SSTR2 expression, and this expression was not significantly associated with tumor-free survival or any tested prognostic factor. Conclusions: Based on the rare and low expression of SSTR2 found in primary UM specimens and in UM cell lines, we conclude that SSTR2 is not widely expressed in UM. Furthermore, SSTR2 expression was not associated with tumor-free survival and prognostic factors. Therefore SSTR2 is not suited as prognostic marker or therapeutic target in UM. </description>
    </item> <item>
      <title>Increased expression of p73Δex2 transcript in uveal melanoma with loss of chromosome 1p (Article)</title>
      <link>http://repub.eur.nl/res/pub/29925/</link>
      <pubDate>2008-06-01T00:00:00Z</pubDate>
      <description>The loss of chromosome 1p and chromosome 3 is associated with metastatic disease and decreased survival of uveal melanoma (UM) patients. The p53 homologues, p73 and p63, are located on chromosomes 1p and 3q, respectively. Both are able to activate p53 target genes, resulting in growth arrest, apoptosis and differentiation. N-terminally truncated isoforms of these genes may act as dominant negative inhibitors of wild-type p53 and transactivating activity. Although, p53 is frequently involved in several malignancies it does not play a major role in UM. Altered expression has been reported for both p63 and p73 in various malignancies. In this study, fluorescent in-situ hybridization was performed to identify gains or losses of p63 and p73 loci in UM. The expression of the different p63 and p73 isoforms was evaluated by reverse transcriptase PCR followed by Southern blot analysis. Furthermore, the expression pattern of the various ΔTAp73 transcripts was analysed in seven primary UMs and 11 UM-derived cell lines using isoform-specific real-time PCR. Our results indicated that the isoform p73Δex2/3 was abundantly expressed and a relative loss of the p73 locus was associated with the upregulation of p73Δex2 and TAp73 transcripts. N-terminal transactivation forms of both p73 and p63 were observed in primary and metastasis-derived cell lines, as well as in primary melanomas, but in only one of the cell lines a ΔNp63 mRNA transcript was observed. Our data suggest a potential function of p73 deletion transcripts in UM progression. </description>
    </item> <item>
      <title>Molecular cytogenetic analysis of archival uveal melanoma with known clinical outcome (Article)</title>
      <link>http://repub.eur.nl/res/pub/29369/</link>
      <pubDate>2008-03-01T00:00:00Z</pubDate>
      <description>Uveal melanoma (UM) is the most common primary intraocular tumor in the Western world. Cytogenetically, this tumor is characterized by typical chromosomal aberrations such as loss of 1p, 3, and 6q, and gain of 6p and 8q. Routinely, karyotyping and fluorescent in situ hybridization (FISH) on fresh tumor-biopsies are used to identify chromosomal changes. In addition, archival UM samples can be examined using comparative genomic hybridization (CGH). In the presented study, we used CGH on a series of 46 archival uveal melanomas to identify chromosomal changes. In 44 tumors aberrations were present and classic prognostic markers as loss of 1p (12 tumors, 26.1 %), monosomy 3 (26 tumors, 56.5%), loss of 6q (10 tumors, 21.7%), and gain of chromosome arm 8q (27 tumors, 58.7%) were observed. Gain of chromosome arms 18q or 21q was found in three UMs. Multiplex ligation-dependent probe amplification (MLPA), a novel technique in UM, was performed to verify this low number of chromosome 18 and 21 abnormalities, but we could not confirm the previously reported gain of 18q11.2 and 21q11.2 as poor prognostic factors in UM. </description>
    </item> <item>
      <title>Regional deletion and amplification on chromosome 6 in a uveal melanoma case without abnormalities on chromosomes 1p, 3 and 8 (Article)</title>
      <link>http://repub.eur.nl/res/pub/29960/</link>
      <pubDate>2008-02-01T00:00:00Z</pubDate>
      <description>Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. Loss of the long arm and gain of the short arm of chromosome 6 are frequently observed chromosomal aberrations in UM, together with loss of chromosome 1p36, loss of chromosome 3 and gain of chromosome 8. This suggests the presence of one or more oncogenes on 6p and tumor suppressor genes at 6q that are involved in UM development. Both regions, however, have not been well defined yet. Furthermore in other neoplasms gain of 6p and loss of 6q are frequently occurring events. In this case report, we describe the delineation of a partial gain on chromosome 6p and a partial deletion on 6q in a UM with the objective to pinpoint smaller candidate regions on chromosome 6 involved in UM development. Conventional cytogenetics, comparative genomic hybridization (CGH) and fluorescence in-situ hybridization (FISH) were used to delineate regions of loss and gain on chromosome 6 in this UM patient. With conventional cytogenetics a deleted region was found on chromosome 6q that was further delineated to a region ranging from 6q16.1 to 6q22 using CGH and FISH. A region of gain from 6pter to 6p21.2 was also demarcated with CGH and FISH. No other deletions or amplifications on recurrently involved chromosomes were found in this patient. This study indicates the presence of one or more tumor suppressor genes on chromosomal region 6q16.1-6q22 and the presence of one or more oncogenes on chromosomal region 6pter-6p21.2, which are likely to be important in UM and other tumors. </description>
    </item> <item>
      <title>Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma (Article)</title>
      <link>http://repub.eur.nl/res/pub/29326/</link>
      <pubDate>2008-01-01T00:00:00Z</pubDate>
      <description>PURPOSE. Mutations in the genes that control cell proliferation in cutaneous melanoma are generally uncommon in uveal melanoma. Despite the absence of known activating mutations, the RAF-MEK-ERK, or mitogen-activated protein kinase (MAPK), pathway is usually activated in uveal melanoma. An assay with increased potential to identify mutations is now available, and this study was therefore conducted to reanalyze uveal melanoma cell lines and primary tumors for this mutation. METHODS. Eleven uveal melanoma cell lines and 45 primary uveal melanomas were analyzed for mutations in exon 15 of the B-RAF gene by using pyrophosphorolysis-activated polymerization (PAP). Mutations were validated by sequencing of the PAP product. RESULTS. B-RAF mutations were detected in cell lines OCM-1 and -3 (V600E) and in six primary uveal melanomas. The V600K mutation was detected in one primary uveal melanoma, for which the V600E assay turned out to be sensitive as well. Direct sequencing of the exon 15 PCR product did not reveal the mutations found with the PAP-assay, indicating a low frequency of the mutant allele in primary samples. CONCLUSIONS. Because of the very sensitive PAP technology, B-RAF mutations were found in cell lines and primary uveal melanomas, which suggests that they may occasionally play a role in the activation of the MAPK pathway in uveal melanoma and indicates a higher prevalence of B-RAF mutations in uveal melanoma than was reported earlier. However, the relative scarcity of the B-RAF mutation excludes an elemental role for this mutation in uveal melanoma. Copyright </description>
    </item> <item>
      <title>Prognostic Factors in Uveal Melanoma (Doctoral Thesis)</title>
      <link>http://repub.eur.nl/res/pub/20829/</link>
      <pubDate>2006-04-19T00:00:00Z</pubDate>
      <description>Uveal melanoma is the most common intra-ocular tumour in the western world with an annual incidence of seven per million. Approximately 50% of the patients treated by enucleation dye eventually due to metastatic disease. Besides enucleation there are nowadays more conservative treatment methods aimed at sparing the affected eye and retaining vision, s.a. transpupillary thermotherapy (TTT), plaque radiotherapy, proton beam or stereotactic radiotherapy. The effect of radiotherapy in uveal melanoma cell lines and primary uveal melanoma was described in the first part of this thesis. The second part of this thesis focuses on identification of clinical and genetic prognostic parameters. It concentrates on parameters that identify patients at high risk of metastatic disease, in particular. Several prognostic markers have been associated with disease free survival. We describe the analysis of 120 uveal melanomas of patients treated with enucleation for chromosomal!
  changes using conventional cytogenetics, FISH and CGH techniques. Concurrent loss of chromosome region 1p and monosomy of chromosome 3 was the strongest predictor for disease free survival of uveal melanoma patients.
The last part focuses on delineation of critical regions and genes of interest. Besides monosomy 3 some tumours may show partial loss of chromosome 3. Two regions, one on the p-arm and one on the q-arm, might be involved in metastases. We studied the partial aberrations observed in uveal melanoma cell lines. A region on chromosome 3q was delineated and reduced the size of the smallest region of overlap compared with literature. The strong correlation between concurrent loss of chromosome region 1p36 and monosomy 3 was suggestive for genes encoded on these chromosomes that might play a role in tumour progression. Two genes, p73 and p63, located on chromosome 3q24 and 1p36 respectively were investigated. Furthermore, we describe mutation analysis of BRAF in thirty-three primary uveal melanoma and commonly used uveal melanoma cell lines.</description>
    </item> <item>
      <title>Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients. (Article)</title>
      <link>http://repub.eur.nl/res/pub/13853/</link>
      <pubDate>2005-12-01T00:00:00Z</pubDate>
      <description>PURPOSE: Uveal melanoma is a highly malignant disease with a mortality rate of 50% at 10 to 15 years. Previous studies have shown that chromosomal changes are associated with decreased survival of the patient. However, in these studies the small number of tumors analyzed did not allow robust statistical analysis. In the present study, the independent numerical changes in chromosomes 1, 3, 6, and 8 on disease-free survival (DFS) was assessed in a large series of patients with uveal melanoma. METHODS: One hundred twenty tumors from patients with uveal melanoma were analyzed for numerical changes in chromosomes 1, 3, 6, and 8, with cytogenetic analysis, fluorescent in situ hybridization, and/or comparative genomic hybridization. Data were correlated with disease outcome in univariate and multivariate analyses, by Kaplan-Meier and Cox regression analyses. RESULTS: At a mean follow-up time of 45 months, 42 patients had died or had metastatic disease. In the univariate analysis, loss of chromosome 3, gain of 8q, largest tumor diameter, or the presence of epithelioid cells was associated with a decreased DFS. In the multivariate analysis, the effect of monosomy 3 on survival was largely modified by changes in 1p36. Regarding all chromosomal changes, only the concurrent loss of the short arm of chromosome 1 and all of chromosome 3 was an independent prognostic parameter for disease-free survival (P &lt; 0.001). CONCLUSIONS: In uveal melanoma, concurrent loss of the short arm of chromosome 1 and all of chromosome 3 is an independent predictor of decreased DFS.</description>
    </item> <item>
      <title>Dose fractionation effects in primary and metastatic human uveal melanoma cell lines (Article)</title>
      <link>http://repub.eur.nl/res/pub/10236/</link>
      <pubDate>2003-01-01T00:00:00Z</pubDate>
      <description>PURPOSE: To investigate the effects of split-dose irradiation on primary
      and metastatic uveal melanoma cell lines, with a clonogenic survival
      assay. METHODS: Appropriate cell concentrations of four primary and four
      metastatic human uveal melanoma cell lines were cultured for irradiation
      with single doses and with two equal fractions separated by 5 hours. After
      irradiation, colony formation was allowed for 7 to 21 days. Two cutaneous
      melanomas were also tested for comparison. All survival curves were
      analyzed using the linear quadratic (LQ) model. Specific parameters for
      the intrinsic radiosensitivity (alpha-component, SF2), for the capacity of
      repair of DNA damage (beta-component), as well as the alpha/beta ratio
      were calculated. RESULTS: After single-dose irradiation a wide range in
      the values of the alpha- and beta-component was obtained for both primary
      and metastatic uveal melanomas, which resulted in a wide range of
      alpha/beta ratios. In contrast, calculations based on split-dose data,
      with which the beta-component could be estimated independent of the
      alpha-component, indicated that estimates for the capacity of sublethal
      DNA damage repair was very similar in all cell lines. This indicated that
      intrinsic factors dominated the radiosensitivity of these cell lines.
      Split-dose irradiation had little influence on the intrinsic
      radiosensitivity (alpha-component), but cell survival increased for all
      cell lines. For the two cutaneous melanomas comparable split-dose results
      were obtained. CONCLUSIONS: For both primary and metastatic uveal melanoma
      cell lines, data from single and fractionated doses indicate large
      variations in radiosensitivity, which are mainly dominated by the
      intrinsic radiosensitivities. Doses of approximately 8 Gy in five
      fractions would be sufficient to eradicate 10(9) cells (approximately 1
      cm3) of the most radioresistant tumor cell lines, but this schedule is an
      overkill for the radiosensitive tumor cell lines. Based on specific
      morphologic and histologic tumor markers, more individualized dose
      fractionation schedules could improve the therapeutic ratio for uveal
      melanomas.</description>
    </item>
  </channel>
</rss>